ClinicalTrials.gg
Not yet recruitingNCT07470840Updated Oct 1, 2026

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

A Phase 2 interventional study of Stereotactic Body Radiation Therapy (SBRT) and Anlotinib in Locally Advanced or Metastatic Renal Cell Carcinoma, sponsored by Fujian Cancer Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Fujian Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 235 studies in Carcinoma, Renal Cell with a site in China — 112 open to participants now, 142 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.

Planned enrollment
155th of 190
27 · median 66
Started
2027
the only one that year
Phase 2
68 of 235
31 open now
Primary completion
2029-02
later than 131 of 141 live
Registered
202nd of 235
by date

Among the 235 studies in Carcinoma, Renal Cell with a site in China, this one is the 155th largest by planned enrollment of the 190 interventional ones that give a count, is the only one that started in 2027, is one of 68 in phase 2, reaches primary completion later than 131 of the 141 other live ones, and was the 202nd registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

112 of the 235 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Carcinoma, Renal Cell with a site in China, or all of them as a file.
02

Study summary

To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.

03

Conditions studied

  • Locally Advanced or Metastatic Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 80 years, regardless of sex.
  2. or cytologically confirmed locally advanced/ renal cell carcinoma (RCC) inoperable/refused for surgery, or post-operative locally recurrent/metastatic RCC; pathological types include clear cell carcinoma and papillary renal cell carcinoma.
  3. performance status 0 or 1.
  4. At least 50% of all evaluable metastatic lesions are eligible for stereotactic body radiation therapy (SBRT).
  5. No to radiotherapy, targeted therapy or immunotherapy.
  6. At least one radiologically according to (RECIST) version 1.1.
  7. Capable and willing to comply with the study protocol including scheduled visits, treatment plan, laboratory tests and other study-related procedures during the study period.
  8. Signed written form.

Exclusion criteria

Exclusion Criteria:

  1. With to targeted or immunotherapeutic drugs.
  2. A history of other malignant diseases in the recent 5 years, except for cured skin cancer and carcinoma in situ of the cervix.
  3. With active diseases, organ transplantation, or other diseases requiring therapy or long-term hormone therapy.
  4. Extensive diffuse with an expected survival of less than 3 months.
  5. A history of uncontrolled epilepsy, central nervous system diseases or mental disorders, whose clinical severity is judged by the investigator to potentially hinder the signing of the form or affect the patient's compliance with oral medication.
  6. With severe uncontrolled recurrent infections or other serious uncontrolled concomitant diseases.
  7. Allergic to any component of the study drugs.
  8. The subject's baseline blood routine and biochemical indicators do not meet the following criteria: ≥80g/L; (ANC) ≥1.5×10⁹/L; ≥100×10⁹/L; and AST ≤2.5 times the ; serum total \<1.5 times the upper limit of normal; serum creatinine \<2 times the upper limit of normal.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    SBRT combined with Anlotinib and Bemarituzumab

    Interventions: 1. Radiation: stereotactic body radiotherapy (SBRT) 2. Drug: Anlotinib 3. Drug: Bemarituzumab

    Radiation: Stereotactic Body Radiation Therapy (SBRT) · Drug: Anlotinib · Drug: Bemarituzumab

Interventions

  • RadiationStereotactic Body Radiation Therapy (SBRT)

    Dose fractionation: 39-48Gy/3f or 40-50Gy/5f, alternative 20-50Gy/5f if OAR dose-limited. Dose adjusted per radiation toxicities during treatment.

  • Oral anti-angiogenic agent, 12 mg qd fasting, 21d/cycle (2w on/1w off)

  • Intravenous PD-1 inhibitor, 1200 mg q3w, 60min infusion

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Time frame: Assessed at baseline, before the second/fourth cycle of targeted-immunotherapy and at regular intervals during consolidation therapy follow-up throughout the study, from enrollment to 36 month.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  2. Disease Control Rate (DCR)

    Time frame: Assessed at baseline, before the second/fourth cycle of targeted-immunotherapy and regular follow-up during consolidation therapy, from enrollment to 36 month.

  3. Overall Survival (OS)

    Time frame: Followed up for the entire study period until patient death or study conclusion, from enrollment to 36 month.

  4. Objective Response Rate in the Field of Irradiation

    Time frame: Assessed at baseline, post-SBRT (before the 2nd cycle of targeted-immunotherapy) and regular follow-up during consolidation therapy, from enrollment to 36 month..

  5. Objective response rate (ORR) of irradiated versus non-irradiated lesions assessed by RECIST v1.1

    Time frame: Baseline, before cycle 2 and cycle 4 of immunotherapy (each cycle is 21 days), and up to 36 months.

  6. Incidence of treatment-related adverse events (TRAEs) assessed by CTCAE v5.0

    Time frame: From baseline through study treatment period, up to 2 years.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Feb 2029, 24 months later.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 24 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2026
First posted
Mar 13, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Feb 1, 2029
CompletionEst.
Jun 1, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07470840
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Feb 1, 2029 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Jinluan Li, MD
Contact
lijinluan@fjmu.edu.cn
+86-15159628678
Shushang Chen, MD
Contact
121257401@qq.com
+86-18960939103
Jiunluan Li, MD
principal investigator · Fujian Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion